THX Pharma (STU:3VG) 6-Month Price Index: 1.11 (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3VG THX Pharma STU:3VG
39 GF Score
Price €3.32
! 1 Warning Sign
View Full Analysis

What is THX Pharma 6-Month Price Index?

THX Pharma STU:3VG +3.09% 39 6-Month Price Index is 1.11 as of Sep. 22, 2026. GuruFocus rates STU:3VG with a GF Score™ of 39/100. The stock has 1 warning sign investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-22), THX Pharma's 6-Month Price Index is 1.11.

THX Pharma  (STU:3VG) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

THX Pharma 6-Month Price Index Related Terms

STU:3VG vs VRTX, REGN, MRNA: 6-Month Price Index Comparison

For the Biotechnology subindustry, THX Pharma's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

STU:3VG
39GF Score
THX Pharma STU:3VG
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

THX Pharma  (STU:3VG) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 1.11 mean?
THX Pharma (STU:3VG) has a 6-Month Price Index of 1.11 as of Sep. 22, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on THX Pharma and its competitors.
Is THX Pharma's 6-Month Price Index too high?
THX Pharma's current 6-Month Price Index is 1.11. Overall, THX Pharma has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does THX Pharma's 6-Month Price Index compare to VRTX and REGN?
THX Pharma's 6-Month Price Index of 1.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on THX Pharma and its competitors. THX Pharma's current 6-Month Price Index is 1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is THX Pharma stock overvalued right now?
THX Pharma (STU:3VG) has a current 6-Month Price Index of 1.11. The current 6-Month Price Index is 1.11. THX Pharma's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For THX Pharma (STU:3VG), the current 6-Month Price Index is 1.11 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

THX Pharma Business Description

Other Exchanges ALTHX:France
Address 60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008
Theranexus SA, which trades under the ticker ALTHXp and has rebranded as THX Pharma, is a France-based clinical-stage biopharmaceutical company focused on central nervous system disorders. Its therapeutic approach combines two distinct drugs in a single treatment: one targeting neuronal activity and another targeting glial cells, aiming to address conditions where neuron-glia interactions play a role. Its pipeline includes THN102 for excessive daytime sleepiness in Parkinson's disease, THN201 for neurocognitive disorders in Alzheimer's disease, and THN101 for neuropathic pain. The company develops these candidates through clinical trials and seeks to advance them toward regulatory approval and commercialization, generating value through partnerships and licensing arrangements rather than marketed product sales. Its activities are centered in France, with development efforts directed at global CNS markets.
39GF Score

Get the complete analysis for STU:3VG

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price